TALENT Trial Shares Breast Cancer Treatment Results
New results from the Phase 2 TALENT study provide data on trastuzumab deruxtecan use in early-stage breast cancer patients.
Updated on Oct. 23, 2026 in Cancer
The Phase 2 TALENT trial has presented its findings regarding the use of trastuzumab deruxtecan in patients with HER2-low, hormone receptor-positive early-stage breast cancer. Results were shared with the global medical community at the ESMO Congress 2026.
Why it matters
This trial sought to determine if antibody-drug conjugate therapy could effectively treat high-risk disease, prompting the addition of an arm incorporating chemotherapy. These results offer clinical insights into the efficacy and safety profile of different treatment combinations for this specific patient population.
The TALENT trial reported pathological complete response rates of 7%, 3%, and 9% across three treatment arms. Objective response rates reached 62%, 66%, and 72% respectively, with grade 3 or greater treatment-related adverse events peaking at 28% in the combination arm.
The players
ESMO Congress 2026
This is an international medical conference held in Madrid, Spain, where oncology researchers present findings from ongoing clinical trials.
Fred Hutchinson Cancer Center
This research institution based in Seattle, Washington, is a central hub for advanced clinical trials and cancer studies.
The details
The study evaluated three distinct arms, including trastuzumab deruxtecan alone, a combination with anastrozole, and an arm that added chemotherapy. Researchers observed three cases of grade 2 interstitial lung disease and increased treatment cycles from 6 to 8 after noting near-pathologic responses.
Timeline
October 23-27, 2026: Trial results were presented at the ESMO Congress in Madrid.
Health Landscape
This research advances the broader investigation into antibody-drug conjugates for HER2-low breast cancer treatment protocols. It provides critical efficacy data that helps refine how clinicians integrate novel agents against standard high-risk therapeutic pathways.
These results provide oncologists with new data regarding the safety and response rates of specific drug combinations for HER2-low breast cancer patients. While not a direct treatment protocol change, the study informs future clinical decisions and the management of treatment-related side effects.
The takeaway
The study underscores the necessity of balancing efficacy with the risk of adverse events like interstitial lung disease when using antibody-drug conjugates. Patients should consult their oncologists to understand how these findings might align with personalized care plans for HER2-low cancer types.
Further reading
Learn more about the latest research and clinical standards in the Cancer section.
